 Shares of Kala Pharmaceuticals Inc. KALA, 39.53 have rocketed higher in for three-straight sessions, toward a more-than 8-fold gain, since the biopharmaceutical company announced positive news regarding its treatment of persistent corneal epithelial defect PCED. The stock exploded up 218.4 on Wednesday, after the Food and Drug Administration accepted the investigational new drug IND application for the PCED treatment, KPI-012, then rose 99.0 on Thursday. 